S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
NASDAQ:MOLN

Molecular Partners News Headlines

$28.55
-1.52 (-5.05%)
(As of 01/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$27.30
$28.58
50-Day Range
$9.99
$31.89
52-Week Range
$9.57
$32.04
Volume
85,463 shs
Average Volume
154,464 shs
Market Capitalization
$921.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Get Molecular Partners News Delivered to You Automatically

Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Molecular Partners Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MOLN
News Sentiment

0.79

0.36

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MOLN Articles
This Week

8

1

MOLN Articles
Average Week



Molecular Partners (NASDAQ:MOLN) News Headlines Today

SourceHeadline
MarketBeat logoMolecular Partners (NASDAQ:MOLN) Shares Gap Down to $30.07
americanbankingnews.com - January 24 at 4:58 PM
MarketBeat logoMolecular Partners AG (NASDAQ:MOLN) Receives Consensus Recommendation of "Buy" from Analysts
americanbankingnews.com - January 24 at 2:18 AM
MarketBeat logoMolecular Partners (NASDAQ:MOLN) Shares Gap Up to $26.50
americanbankingnews.com - January 19 at 11:37 AM
MarketBeat logoMolecular Partners AG (NASDAQ:MOLN) Short Interest Update
americanbankingnews.com - January 18 at 7:28 PM
MarketBeat logoMolecular Partners (NASDAQ:MOLN) Shares Gap Down to $31.89
americanbankingnews.com - January 18 at 12:50 PM
seekingalpha.com logoNovartis and Molecular Partners finalize licensing agreement for COVID-19 candidate
seekingalpha.com - January 18 at 9:20 AM
nasdaq.com logoMolecular Partners AG - ADR Shares Close the Week 93.2% Higher - Weekly Wrap
nasdaq.com - January 17 at 7:57 PM
MarketBeat logoMolecular Partners AG (NASDAQ:MOLN) to Post FY2026 Earnings of ($4.49) Per Share, SVB Leerink Forecasts
americanbankingnews.com - January 17 at 2:54 AM
MarketBeat logoMolecular Partners (NASDAQ:MOLN) Given New CHF 23 Price Target at Credit Suisse Group
americanbankingnews.com - January 14 at 5:25 PM
seekingalpha.com logoMolecular Partners up 7% after investor BVF Partners raises stake through stock transfer
seekingalpha.com - January 14 at 5:20 PM
MarketBeat logoMolecular Partners (NASDAQ:MOLN) Given New $42.00 Price Target at SVB Leerink
americanbankingnews.com - January 14 at 8:52 AM
finance.yahoo.com logoMolecular Partners Reports Disclosure of Major Shareholder as per Swiss Stock Exchange Regulations
finance.yahoo.com - January 13 at 6:05 PM
MarketBeat logoMolecular Partners (NASDAQ:MOLN) Shares Up 6.9%
americanbankingnews.com - January 12 at 3:08 PM
finance.yahoo.com logoMolecular (MOLN), Novartis Post Positive Data From COVID-19 Drug
finance.yahoo.com - January 11 at 3:01 PM
MarketBeat logoMolecular Partners (NASDAQ:MOLN) Shares Gap Up to $21.50
americanbankingnews.com - January 11 at 10:50 AM
reuters.com logoNovartis-Molecular Partners COVID drug could be approved in weeks
reuters.com - January 10 at 8:35 PM
MarketBeat logoMolecular Partners (NASDAQ:MOLN) Reaches New 52-Week High at $21.46
americanbankingnews.com - January 10 at 10:46 AM
finance.yahoo.com logoMolecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19
finance.yahoo.com - January 10 at 10:35 AM
markets.businessinsider.com logoPre-market Movers: AIZ, APR, RVPH, BBLG, MOLN…
markets.businessinsider.com - January 10 at 10:35 AM
reuters.com logoNovartis in-licenses COVID-19 treatment ensovibep from Molecular Partners
reuters.com - January 10 at 10:35 AM
seekingalpha.com logoMolecular Partners, Novartis report positive data from Phase 2 ensovibep study in COVID-19
seekingalpha.com - January 10 at 10:35 AM
markets.businessinsider.com logoMolecular Partners Inks License Deal With Novartis For $580M
markets.businessinsider.com - December 14 at 2:24 PM
benzinga.com logoMolecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology
benzinga.com - December 14 at 9:24 AM
nasdaq.com logoMolecular Partner: Phase 2a Data From Patients Treated With Ensovibep Show Safe And Well-tolerated
nasdaq.com - December 6 at 9:40 AM
markets.businessinsider.com logoMolecular Partners Says Its COVID-19 Antiviral Still Effective Against Positions Mutated In Omicron
markets.businessinsider.com - November 30 at 12:29 PM
finance.yahoo.com logoMolecular Partners Confirms Retained Activity of Ensovibep on the Positions Mutated in Emerging Omicron Variant of SARS-CoV-2 In Vitro
finance.yahoo.com - November 30 at 1:36 AM
msn.com logoThe Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
msn.com - November 16 at 1:29 PM
finance.yahoo.com logoMolecular Partners Provides Update from ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19
finance.yahoo.com - November 16 at 8:28 AM
finance.yahoo.com logoMolecular Partners Announces First Patient Dosed with CD40 Therapeutic Candidate MP0317 in Phase 1 Clinical Trial
finance.yahoo.com - November 4 at 8:49 AM
finance.yahoo.com logoInterim Management Statement Q3 2021 of Molecular Partners: Advancement of COVID-19 Clinical Program and Continued Immuno-Oncology Momentum
finance.yahoo.com - October 28 at 2:10 AM
finance.yahoo.com logoMolecular Partners Present Data Demonstrating Successful Inhibition of COVID19 Viral Variants with Ensovibep at the 2021 ISIRV-WHO Conference
finance.yahoo.com - October 20 at 2:35 AM
businesswire.com logolino Biotech Can Draw on Over 150 Years of Experience in Life Science, Cell Therapy and Diagnostics Thanks to Five Internationally Renowned Industry Experts
businesswire.com - September 15 at 11:01 PM
markets.businessinsider.com logoAbbVie Returns Eye Drug Candidate To Molecular Partners
markets.businessinsider.com - August 9 at 7:45 AM
finance.yahoo.com logoMolecular Partners to Regain Global Rights to Abicipar
finance.yahoo.com - August 9 at 7:45 AM
barrons.com logoMolecular Partners AG
barrons.com - August 1 at 10:41 PM
barrons.com logoMolecular Partners AG ADR
barrons.com - July 30 at 10:28 PM
finance.yahoo.com logoMolecular Partners Shares Development in Ensovibep Program
finance.yahoo.com - July 8 at 11:36 AM
Get Molecular Partners News Delivered to You Automatically

Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.